CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

Presenter

Sumanta K. Pal, MD, FASCO

Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Videos & Slides

ondemand_video

Videos & Slides

2023 ASCO Annual Meeting

bookmark_border

play_arrow

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.

Speaker: Toni K. Choueiri, MD

ondemand_video

Videos & Slides

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

play_arrow

Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.

Speaker: Robert J. Motzer, MD

ondemand_video

Videos & Slides

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

play_arrow

AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer.

Speaker: Naureen Starling, MD, MBBS, FRCP, BSc

ondemand_video

Videos & Slides

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

play_arrow

CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).

Speaker: Laurence Albiges, MD, PhD